Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-24
2011-11-15
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388150
Reexamination Certificate
active
08058402
ABSTRACT:
Provided herein are antibodies, such as fully human antibodies that immunospecifically bind to an hLIGHT polypeptide. Also provided are isolated nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Further provided are vectors and host cells comprising nucleic acids encoding antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided are methods of making antibodies, such as fully human antibodies, that immunospecifically bind to a hLIGHT polypeptide. Also provided herein is a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject an antibody, such as a fully human antibody, that immunospecifically binds to a hLIGHT polypeptide. In preferred embodiments, that anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
REFERENCES:
patent: 6140467 (2000-10-01), Ware
patent: 6235878 (2001-05-01), Nishi et al.
patent: 6346388 (2002-02-01), Brigham-Burke et al.
patent: 6479254 (2002-11-01), Ebner et al.
patent: 6495520 (2002-12-01), Ebner et al.
patent: 6590090 (2003-07-01), Nishi et al.
patent: 6635743 (2003-10-01), Ebner et al.
patent: 6998108 (2006-02-01), Ware
patent: 7118742 (2006-10-01), Ware
patent: 7541441 (2009-06-01), Rosen et al.
patent: 7575745 (2009-08-01), Ware
patent: 2003/0060605 (2003-03-01), Ware
patent: 2003/0215442 (2003-11-01), Fraser et al.
patent: 2004/0009147 (2004-01-01), Ebner et al.
patent: 2004/0038349 (2004-02-01), Hilbert et al.
patent: 2004/0176320 (2004-09-01), Natunen et al.
patent: 2005/0129614 (2005-06-01), Rosen et al.
patent: 2005/0163747 (2005-07-01), Hilbert et al.
patent: 2005/0202462 (2005-09-01), Matsui et al.
patent: 2005/0287605 (2005-12-01), Matsui et al.
patent: 2252786 (2004-08-01), None
patent: WO 97/34911 (1997-09-01), None
patent: WO 98/03648 (1998-01-01), None
patent: WO 99/02563 (1999-01-01), None
patent: WO 99/35262 (1999-07-01), None
patent: WO 99/42584 (1999-08-01), None
patent: WO 00/71151 (2000-11-01), None
patent: WO 01/79496 (2001-10-01), None
patent: WO 02/20615 (2002-03-01), None
patent: WO 02/066050 (2002-08-01), None
patent: WO 2003/089575 (2003-10-01), None
patent: WO 2006/063067 (2006-06-01), None
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Gussow et al. (Methods in Enzymology. 1991; 203: 99-121).
Winkler et al (J. Imm., 265:4505-4514, 2000).
Kellermann et al (Cur. Opin. Biotech., 13:593-597, 2002).
NCBI Database; GenBank Accesion No. AAL10826 (Aug. 19, 2002).
NCBI Database; GenBank Accesion No. AAY33445 (Aug. 5, 2005).
NCBI Database; GenBank Accesion No. AAM46399 (Jun. 2, 2002).
NCBI Database; GenPept Accesion No. PIR: B27594 (Jan. 21, 2000).
Office action from counterpart application in Honduras, Honduran Patent Appln. No. 2009-000414, dated Jan. 19, 2010.
Tamada et al., “Modulation of T-Cell-Mediated Immunity in Tumor and Graft-Versus-Host Disease Models through the LIGHT Co-Stimulatory Pathway,”Nat Med. 6(3):283-9 (2000).
International Search Report mailed May 28, 2008 in counterpart PCT Application No. PCT/US2007/018832.
ABCAM—Product Information for Cat. No. ab17716—Rabbit Anti-LIGHT Polyclonal Antibody (Biotin) (2006).
ABCAM—Product Information for Cat. No. ab18881—Rabbit Anti-LIGHT Polyclonal Antibody (2006).
Abnova Corporation—Product Information for Cat. No. H00008740-M01—Mouse Monoclonal Anti-TNFSFI4 (LIGHT), Clone 4E3 (2008).
Antigenix America Inc.—Product Information for Cat. No. RHF928—Anti-Human LIGHT Polyclonal Antibody, Unconjugated (2006).
Antigenix America Inc.—Product Information for Cat. No. RHF928B—Anti-Human LIGHT Polyclonal Antibody, Biotin Conjugated (2006).
Banks et al., “Lymphotoxin-Alpha-Deficient Mice. Effects on Secondary Lymphoid Organ Development and Humoral Immune Responsiveness,”J Immunol. 155(4):1685-1693 (1995).
Biolegend—Product Information for Cat. No. 318701/318702—Purified Anti-Human CD258 (LIGHT) (2007).
Biolegend—Product Information for Cat. No. 318703/318704—Biotin Anti-Human CD258 (LIGHT) (2007).
Biolegend—Product Information for Cat. No. 318705/318706—PE Anti-Human CD258 (LIGHT) (2007).
Biolegend—Product Information for Cat. No. 318801/318802—Purified anti-human HVEM (TR2) (2010).
Biovision—Product Information for Cat. No. 5607-100—Rabbit Anti-LIGHT Polyclonal Antibody, Unconjugated (2005).
Brown et al., “IL-12 Independent LIGHT Signaling Enhances MHC Class II Disparate CD4+ T Cell Alloproliferation, IFN-γ Responses, and Intestinal Graft-versus-Host Disease,”J. Immunol. 174:4688-4695 (2005).
Browning et al., “Characterization of Lymphotoxin-Alpha Beta Complexes on the Surface of Mouse Lymphocytes,”J Immunol. 159(7):3288-3298 (1997).
Bruggermann et al., “Designer Mice: the Production of Human Antibody Repertoires in Transgenic Animals,”Year Immunol. 7:33-40 (1993).
Castellano et al., “Mechanisms Regulating Expression of the Tumor Necrosis Factor-Related Light Gene. Role of Calcium-Signaling Pathway in the Transcriptional Control,”J Biol Chem. 277(45):42841-42851 (2002).
Cheung et al., “Evolutionarily Divergent Herpesviruses Modulate T Cell Activation by Targeting the Herpesvirus Entry Mediator Cosignaling Pathway,”Proc Natl Acad Sci U S A102(37):13218-13223 (2005).
Clark and Ledbetter “How B and T Cells Talk to Each Other,”Nature367(6462):425-428 (1994).
Clark et al., “Cultured Human Follicular Dendritic Cells. Growth Characteristics and Interactions with B Lymphocytes,”J Immunol. 148(11):3327-3335 (1992).
Cohavy et al., “LIGHT Expression by Mucosal T Cells May Regulate IFN-γ Expression in the Intestine,”J. Immunol. 173:251-258 (2004).
Cohavy et al., “LIGHT is Constitutively Expressed on T and NK Cells in the Human Gut and Can Be Induced by CD2-Mediated Signaling,”J. Immunol. 174:646-653 (2005).
Crowe et al., “A Lymphotoxin-Beta-Specific Receptor,”Science264(5159):707-710 (1994).
De Togni et al., “Abnormal Development of Peripheral Lymphoid Organs in Mice Deficient in Lymphotoxin,”Science. 264(5159):703-707 (1994).
Dohi et al., “Elimination of Colonic Patches with Lymphotoxin Beta Receptor-Ig Prevents Th2 Cell-Type Colitis,”J Immunol. 167(5):2781-2790 (2001).
eBIOSCIENCE—Product Information for Cat. No. 14/6969—Affinity Purified Rabbit anti-Human LIGHT Polyclonal Antibody (2006).
Fava et al., “A Role for the Lymphotoxin/LIGHT Axis in the Pathogenesis of Murine Collagen-Induced Arthritis,”J. Immunol. 171(1):115-126 (2003).
Forster et al., “A putative Chemokine Receptor, BLR1, Directs B Cell Migration to Defined Lymphoid Organs and Specific Anatomic Compartments of the Spleen,”Cell87(6):1037-1047 (1996).
Gommerman et al., “A Role for Surface Lymphotoxin in Experimental Autoimmune Encephalomyelitis Independent of LIGHT,”J. Clin. Invest. 112(5):755-767 (2003).
Granger and Ware, “Turning on LIGHT,”J. Clin. Invest. 108(12):1741-1742 (2001).
Granger et al., “Genomic Characterization of LIGHT Reveals Linkage to an Immune Response Locus on Chromosome 19p13.3 and Distinct Isoforms Generated by Alternate Splicing or Proteolysis,”J. Immunol. 167(9):5122-5128 (2001).
Guo et al., “Cutting Edge: Membrane Lymphotoxin Regulates CD8(+) T Cell-Mediated Intestinal Allograft Rejection,”J. Immunol. 167(9):4796-4800 (2001).
Hsu et al.,
Granger Steven W.
Kato Shinichiro
Ware Carl F.
Duffy Brad
Kyowa Hakko Kirin
La Jolla Institute for Allergy and Immunology
Roylance Abrams Berdo & Goodman LLP
Yu Misook
LandOfFree
Antagonistic human LIGHT-specific human monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonistic human LIGHT-specific human monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonistic human LIGHT-specific human monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4273953